Diabetic Eye Disease Consults: Volume 3, Issue 2

1.00 COPE
60 MINS
$0 FEE
SAVE
Diabetic Eye Disease Consults: Volume 3, Issue 2

Overview

Provider Statement

This continuing education activity is provided by Purdue U


Educational Partner

Vindico Medical Education

Support Statement

This activity is supported by independent medical education grants from Genentech, Inc. and Regeneron Pharmaceuticals, Inc.


Activity Description

The management of patients with diabetic eye disease has changed radically in recent years and continues to advance as new technologies and treatment strategies are developed. The advent of medical therapy for the treatment of diabetic retinopathy (DR) has created a need for improved diagnostic techniques. Widefield imaging and optical coherence tomography angiography offer opportunities for earlier detection and more accurate characterization of diabetic retinal disease. Anti-vascular endothelial growth factor (VEGF) medications are now known to have beneficial effects on both DR and diabetic macular edema, but real-world experience indicates that patients are not yet deriving the full benefits promised by the major clinical trials of these agents. In this publication series, expert eye care professionals will discuss new diagnostic techniques and will evaluate the evidence of US Food and Drug Administration-approved and investigational anti-VEGF therapies.


Target Audience

The intended audience for the activity is optometrists and other health care professionals involved in the treatment of patients with diabetic eye disease.


Learning Objectives

  • Examine new imaging techniques that may improve the diagnosis and assessment of diabetic retinal disease.
  • Review the evidence supporting the treatment of diabetic retinopathy with anti-vascular endothelial growth factor (VEGF) therapy.
  • Assess real-world outcomes of patients who have received anti-VEGF therapy for age-related macular degeneration and diabetic macular edema.
  • Describe emerging approaches to long-term delivery of anti-VEGF therapy in diabetic eye disease.
  • Examine evidence from clinical trials regarding the optimization of anti-VEGF therapy in patients with diabetic macular edema.

Co-Chief Medical Editors

Steven Ferrucci, OD, FAAO
Professor
Southern California College of Optometry at
Marshall B. Ketchum University
Chief of Optometry
Sepulveda VA Ambulatory Care Center
North Hills, CA

Rishi P. Singh, MD*
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH

*Also a Faculty Contributor for this issue.


Guest Contributors

A. Paul Chous, MA, OD, FAAO, CDE
Doctor of Optometry
Chous Eye Care Associates
Certified Diabetes Educator
Tacoma, WA

Lori L. Grover, OD, PhD, FAAO
Dean, Pennsylvania College of Optometry
Salus University
Philadelphia, PA

Adiel Smith, MD
Founder and Vitreoretinal Surgeon
South Florida Retina Institute
Aventura, FL


Reviewer

Ashay Bhatwadekar, MPharm, PhD 


Medical Writer

Valerie Zimmerman, PhD 


Accreditation

Purdue University is approved by the Council on Optometric Practitioner Education (COPE) as an administrator/provider of continuing education (CE).


Credit Designation

This enduring material is COPE-accredited for 1.0 continuing education credits and is approved for one (1) year from the date of original release, November 1, 2019 to November 1, 2020.

COPE ID #: 65824-PS
COPE Event #: 118649

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.


How to Participate in This Activity and Obtain CE Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, read the articles, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Purdue University will issue a CE certificate.


Disclosures

In accordance with the Council on Optometric Practitioner Education Standards for Commercial Support, all CE providers are required to disclose to the activity audience the relevant financial relationships of the planners, reviewers, teachers, and authors involved in the development of CE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest related to the practice of optometry.

The articles in this monograph were composed by medical writer, Valerie Zimmerman, PhD, based on the presentations by Drs. Chous, Grover, Smith, and Singh during a virtual expert panel discussion held in September 2019.

Planning Committee and Faculty report the following relationship(s)

A. Paul Chous, MA, OD, FAAO, CDE
Consulting Fee: ZeaVision, Zeiss
Speakers Bureau: Genentech, Regeneron, ZeaVision, Zeiss
Royalty: ZeaVision

Steven Ferrucci, OD, FAAO
Consulting Fee: AstaReal, Bausch + Lomb, CenterVue, Science Based Health
Speakers Bureau: Alcon, Genentech, Optovue, Regeneron

Lori L. Grover, OD, PhD, FAAO
No relevant financial relationships to disclose.

Rishi P. Singh, MD
Consulting Fee: Alcon/Novartis, Genentech, Optos, Regeneron, Zeiss
Contracted Research: Apellis

Adiel Smith, MD
No relevant financial relationships to disclose.

Reviewer reports the following relationship(s)

Ashay Bhatwadekar, MPharm, PhD
No relevant financial relationships to disclose.

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Purdue University and Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Purdue University and Vindico Medical Education, Office of Medical Affairs Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Purdue University and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Purdue University and Vindico Medical Education. Neither Purdue University and Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CE Questions?

Contact us at:
Purdue University: cmemda@purdue.edu or 765-496-1306
Vindico Medical Education: cme@vindicocme.com or 856-994-9400, ext. 504


Notice

In accordance with the Sunshine Act, effective August 1, 2013 the medical device or pharmaceutical manufacturer that provided support for this CE activity is required to disclose to the federal government the names of physician-participants and the value received for this CE activity. While Purdue University and Vindico Medical Education are not responsible for making this report, as our valued customer we want to advise you that by partaking in this program your name and the computed value of this monograph in the amount of $15.00 may be posted on a website accessible to the public. For more information on this Sunshine Act’s effects on physicians, please visit this web page: http://www.nejm.org/doi/full/10.1056/NEJMp1303523.


CE and Sunshine Act Attestation

I certify that I have personally completed this activity and the posttest/evaluation. I understand that this is not considered CEE and that each state board of optometry defines a limit to the number of hours of verified self instruction per renewal period. I also understand that this attestation may be used by a state’s regulatory body for license renewal and I attest that by submission of this registration form I may be reported to the federal government as receiving a transfer or value in the amount of $15.00 for participating in this CE activity.